Bristol Myers Squibb Deploys Anthropic’s Claude AI to Transform Drug Development
Bristol Myers Squibb has rolled out Anthropic's Claude AI across its workforce of 30,000, reshaping drug discovery and development processes. This partnership highlights the growing importance of agentic AI in regulated industries.
More from this archive
Google’s Gemini 3.5 Flash Challenges AI Rivals with Competitive Pricing
Google's Gemini 3.5 Flash scores 55 on AI intelligence benchmarks and offers significant cost advantages over rivals, potentially…
Nvidia’s Q1 Earnings: Focus Shifts to Crucial Q2 Guidance
As Nvidia prepares to release its fiscal Q1 2027 results, all eyes are on the guidance for Q2…
OpenAI Expedites IPO Plans Amidst Growing AI Market Competition
OpenAI is accelerating its IPO timeline, preparing for a confidential draft prospectus with support from Goldman Sachs and…
Elon Musk to Appeal Court Ruling Against OpenAI’s Sam Altman
Elon Musk plans to appeal a jury decision that dismissed his claims against OpenAI, raising fundamental issues about…
The archive
sorted by latest
European Commission Unveils Guidelines for High-Risk AI Classification
GPUBeat Desk · 2 min
Rising AI Costs Challenge OpenAI and Anthropic’s IPO Valuations
GPUBeat Desk · 3 min
OpenAI Gears Up for $1T IPO Filing Amid Competitive AI Landscape
GPUBeat Desk · 2 min
Emerging Chinese AI Labs Threaten OpenAI and Anthropic IPOs
GPUBeat Desk · 2 min
AI Super PACs Escalate Rivalries Ahead of Midterm Elections
GPUBeat Desk · 3 min